Drug General Information |
Drug ID |
D08BVM
|
Former ID |
DIB000954
|
Drug Name |
TTP-355
|
Synonyms |
Glucokinase activator (type 2 diabetes), TransTech Pharma
|
Indication |
Diabetes [ICD9: 253.5, 588.1; ICD10:E23.2, N25.1]
|
Discontinued in Phase 2 |
[1]
|
Company |
TransTech Pharma Inc
|
Target and Pathway |
Target(s) |
Glucokinase |
Target Info |
Activator |
[2]
|
KEGG Pathway
|
Glycolysis / Gluconeogenesis
|
Galactose metabolism
|
Starch and sucrose metabolism
|
Amino sugar and nucleotide sugar metabolism
|
Butirosin and neomycin biosynthesis
|
Metabolic pathways
|
Biosynthesis of antibiotics
|
Carbon metabolism
|
Insulin signaling pathway
|
Insulin secretion
|
Prolactin signaling pathway
|
Glucagon signaling pathway
|
Type II diabetes mellitus
|
Maturity onset diabetes of the young
|
Central carbon metabolism in cancer
|
Pathway Interaction Database
|
FOXA2 and FOXA3 transcription factor networks
|
HIF-1-alpha transcription factor network
|
PathWhiz Pathway
|
Nucleotide Sugars Metabolism
|
Starch and Sucrose Metabolism
|
Galactose Metabolism
|
Trehalose Degradation
|
Reactome
|
Regulation of gene expression in beta cells
|
Glucose transport
|
Glycolysis
|
WikiPathways
|
SIDS Susceptibility Pathways
|
Glycolysis and Gluconeogenesis
|
MAPK Signaling Pathway
|
Regulation of beta-cell development
|
Metabolism of carbohydrates
|
Hexose transport
|
References |
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025266) |
---|
REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025266) |